Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

Widmark, Anders; Klepp, Olbjørn; Solberg, Arne; Damber, Jan Erik; Angelsen, Anders; Fransson, Per; Lund, Jo Åsmund; Tasdemir, Ilker; Høyer, Morten; Wiklund, Fredrik; Fosså, Sophie D.

doi:10.1016/s0140-6736(08)61815-2

Cited by 778 publications

(456 citation statements)

References 31 publications

Supporting

Mentioning

409

Contrasting

Unclassified

Order By: Relevance

“…In addition all patients included in the SPCG-7 trial received 3 months with neo-adjuvant androgen deprivation therapy. 9 The RT regime at our institution at that time was according to the SPCG-7 trial fractionated megavolt photon …”

mentioning

confidence: 99%

Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients

Lilleby

Stensvold

Mills

et al. 2013

Intl Journal of Cancer

View full text Add to dashboard Cite

Detection of pretreatment disseminated cells (pre-DTC) reflecting its homing to bone marrow (BM) in prostate cancer (PCa) might improve the current model to predict recurrence or survival in men with nonmetastatic disease despite of primary treatment. Thereby, pre-DTC may serve as an early prognostic biomarker. Post-treatment DTCs (post-DTC) finding may supply the clinician with additional predictive information about the possible course of PCa. To assess the prognostic impact of DTCs in BM aspirates sampled before initiation of primary therapy (pre-DTC) and at least 2 years after (post-DTC) to established prognostic factors and survival in patients with PCa. Available BM of 129 long-term follow-up patients with T1-3N0M0 PCa was assessed in addition to 100 BM of those in whom a pretreatment BM was sampled. Patients received either combined therapy [n 5 81 (63%)], radiotherapy (RT) with different duration of hormone treatment (HT) or monotherapy with RT or HT alone [n 5 48 (37%)] adapted to the criteria of the SPCG-7 trial. Mononuclear cells were deposited on slides according to the cytospin methodology and DTCs were identified by immunocytochemistry using the pancytokeratin antibodies AE1/AE3. The median age of men at diagnosis was 64.5 years (range 49.5-73.4 years). The median long-term follow-up from first BM sampling to last observation was 11 years. Categorized clinically relevant factors in PCa showed only pre-DTC status as the statistically independent parameter for survival in the multivariate analysis. Pre-DTCs homing to BM are significantly associated with clinically relevant outcome independent to the patient's treatment at diagnosis with nonmetastatic PCa.Prostate cancer (PCa) is among the most commonly occuring malignancies in the world. It has a long natural course and its heterogeneous tumor biology leads to considerable underand overtreatment. In curatively treated patients up to 30% of men with localized PCa will encounter recurrence and metastatic deposits are preferred detected inbone. 1 Therefore, additional prognostic biomarkers are urgently needed to improve the standard clinical decision model used in routine [T-category, Gleason score, serum prostate-specific antigen (PSA) and bone scan 2 .The prevalence of disseminated tumor cells (DTCs) in bone marrow (BM) has shown clinical significant relevance when correlated to biochemically defined progression in PCa. 3,4 In one of our previous studies, Berg et al. 5 demonstrated a clinical correlation between presence pretreatment DTCs, dichotomized Gleason score and development of metastatic disease at follow up in nonmetastatic PCa.Several studies have also confirmed the potential of circulating tumor cells (CTC) detection as a monitoring method for treatment response in castration-resistance PCa. 6,7 In this study, we investigated the prognostic value of the prevalence of DTCs in BM of nonsurgical putatively curative treated men with a sufficient long-term follow-up. Methods and PatientsFor the current analysis, we included patients who had T1-3...

show abstract

mentioning

confidence: 99%

Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients

Lilleby

Stensvold

Mills

et al. 2013

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The SPCG-7 and intergroup MRC PR3/PR07 studies randomised men with predominantly localised (SPCG) or predominantly locally advanced (MRC) disease to hormone therapy alone, or to hormone therapy plus radiotherapy. In both trials, men who received radiotherapy had significantly better overall survival than men treated with hormone therapy alone [3,22]. Thus, at least in the context of locally advanced disease, radical radiotherapy prolongs survival and conceivably might cure some men.…”

Section: Evidence Versus Belief; Does Definitive Local Therapy Cure Pmentioning

confidence: 99%

Radiotherapy for Prostate Cancer: is it ‘what you do’ or ‘the way that you do it’? A UK Perspective on Technique and Quality Assurance

et al. 2016

View full text Add to dashboard Cite

“…4 For the purpose of this side study, we identified 125 men who were randomized to the RT arm at our institution (The Norwegian Radium Hospital, NRH). In relation to a scheduled 5-year post-RT visit, nonmetastatic subjects, who still used AA as their only anticancer agent, were asked to complete a questionnaire (n ¼ 89).…”

Section: Patient Selectionmentioning

confidence: 99%

“…1,2 Such a comparison has not been performed in patients who receive an oral nonsteroidal antiandrogen (AA) adjuvant to definitive radiotherapy (RT) for nonmetastatic prostate cancer (PCa). Such combined treatment may improve the overall survival compared with RT alone 3 or AA alone 4 in patients with high risk of relapse.…”

Section: Introductionmentioning

confidence: 99%

Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

Berg

Dahl

Bruland

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

We assessed self-reported health-related quality of life (HRQoL) and longitudinal changes in sex hormones among 86 prostate cancer (PCa) patients without distant metastases 5 years after radiotherapy (RT) combined with ongoing antiandrogen (AA) treatment. HRQoL outcomes were compared with scores from age-matched controls without a cancer diagnosis (NORM). Compared with NORM, patients scored statistically (Po0.05) and clinically (effect size X0.4) lower on sexual domains, and statistically (Po0.05) lower on physical function and vitality. Estimated free testosterone and measured serum estradiol had increased from baseline in most patients, but did not correlate with HRQoL outcomes 5 years after the start of treatment.

show abstract

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

Cited by 778 publications

References 31 publications

Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients

Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients

Radiotherapy for Prostate Cancer: is it ‘what you do’ or ‘the way that you do it’? A UK Perspective on Technique and Quality Assurance

Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

Contact Info

Product

Resources

About